Sep 2026· Clinical Journal of Oncology Nursing· Vol 30 5, pp.
347-351
· 0 citations
Medicine
TL;DR
Tarlatamab-dlle (tarlatamab), a bispecific T-cell engager targeting delta-like ligand 3, offers a novel therapeutic option f.
Abstract
Extensive-stage small cell lung cancer (ES-SCLC) remains highly aggressive and has a poor prognosis. Tarlatamab-dlle (tarlatamab), a bispecific T-cell engager targeting delta-like ligand 3, offers a novel therapeutic option f.
A large number of patients with small cell lung cancer are diagnosed with atypical neuroendocrine or non-neuroendocrine subtypes, which is an aggressive malignancy characterized by rapid progression, early metastasis, and molecular heterogeneity.
Anna M. Dmitrieva, Qian Yang, Ramona Lesch et al.· Oncology Research· 0 citations
Evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy.
S. Kaneko, Naoki Furuya, Y. Sugiura et al.· Thoracic Cancer· 0 citations
Cell and immune therapies have transformed the outcomes of patients with lymphoma, but the majority of patients do not have durable benefit. Here, we provide our perspective on key challenges in personalizing cell and immune therapy approaches for lymphoma through discovery, validation, and clinical deployment of micro...
Xu-Bin Li, Christopher R. Flowers, Michael R. Green· Blood Cancer Discovery· 0 citations
Pemetrexed, a standard antifolate chemotherapy for non‐squamous non‐small cell lung cancer (NSCLC), is often limited by acquired resistance. We investigated whether SRC kinase mediates pemetrexed resistance and whether SRC inhibition can suppress survival signaling in pemetrexed‐resistant NSCLC cells.
Jeongmin Seo, Kui-Jin Kim, Se Hyun Kim et al.· Thoracic Cancer· 0 citations